Pravin T.p Kaumaya

This early-stage trial is testing a vaccine designed to help the immune system recognize and attack HER2-positive breast cancer cells. The vaccine contains two small pieces of the HER2 protein, similar to existing drugs, to trigger an immune response. The study will enroll 36 adu…

This phase 1 trial tests a vaccine made from two HER2 protein fragments in people with advanced breast or esophageal cancers that have spread or cannot be removed. The vaccine aims to train the immune system to recognize and attack HER2-positive tumor cells. Participants receive …